Kestra Medical Technologies, Ltd. reported preliminary financial results for the second quarter fiscal 2026, showing significant growth in revenue and gross profit.
Revenue is expected to grow by over 50% in the second quarter, reaching $22.2 to $22.6 million compared to $14.7 million in the previous year period.
Gross profit is expected to increase to $11.0 to $11.4 million, with a notable improvement in gross margin reaching 50.0%.
Revenue Growth
Revenue is projected to increase by over 50% in the second quarter, reflecting strong commercial momentum and market penetration.
Gross Margin Improvement
Gross margin is expected to rise to 50.0%, indicating positive leverage and attractive unit economics in the business model.
Operational Loss
Loss from operations is expected to be $31.6 to $32.0 million compared to $19.1 million in the previous year period.
- The significant revenue growth and improved gross margin demonstrate Kestra's successful commercial execution and market expansion.
- The strong financial performance reflects the company's ability to maintain a competitive position in the wearable defibrillator market and drive sustainable growth.
- With cash and cash equivalents at approximately $175 million, Kestra is well-positioned for future strategic investments and operational enhancements.
Kestra Medical Technologies' preliminary financial results for the second quarter of fiscal 2026 underscore a period of robust growth and operational effectiveness. The company's performance reflects a positive trajectory in revenue generation and gross margin improvement, positioning Kestra for continued success in the wearable medical device market.